CJC-1295 / Ipamorelin
Growth Hormone Secretagogue Combination
Also known as: Modified GRF 1-29 (CJC-1295), CJC/Ipa
Last updated May 4, 2026
What is CJC-1295 / Ipamorelin?
If you’re in your late 30s or 40s and noticing that recovery takes longer and sleep is lighter, CJC-1295/Ipamorelin is the growth hormone peptide protocol you’ll encounter most often. Here’s what the research actually supports.
CJC-1295 and Ipamorelin are growth hormone secretagogues — they stimulate your pituitary gland to produce more growth hormone naturally. CJC-1295 works through GHRH receptors. Ipamorelin works through ghrelin receptors. They target different pathways, which is why the combination is the most commonly prescribed GH peptide protocol. Unlike synthetic HGH (which replaces your natural production), these peptides enhance your body’s own GH output.
What Does the Research Actually Show?
Clinical research demonstrated combined CJC-1295 and Ipamorelin stimulation produces synergistic GH output significantly greater than either compound alone — one of the few peptide combinations with genuine clinical evidence for the pairing itself. Unlike older secretagogues (GHRP-2, GHRP-6), Ipamorelin primarily stimulates GH without significantly elevating cortisol, prolactin, or other unwanted hormones. The result is a cleaner side-effect profile alongside the synergistic effect.
GH secretion is linked to deep sleep. Mechanistically supported and widely reported by patients and practitioners.
Mechanistically supported through GH/IGF-1 pathways but limited RCT-level evidence for this combination specifically.
It’s worth noting: without controlled human trials, we can’t rule out that practitioner-reported benefits are placebo, coincidental with other interventions or overstated. The mechanistic rationale is sound, but sound rationale isn’t proof.
How Is CJC-1295 / Ipamorelin Administered?
| Route | Subcutaneous injection |
| Dosage Range | CJC-1295: 100–300 mcg, Ipamorelin: 100–300 mcg |
| Frequency | 1–2x daily, typically before bed |
| Cycle Length | 8–12 weeks on, 4 weeks off |
| Time to Effect | Sleep improvements often within 1–2 weeks, body composition changes 4–8 weeks |
| Note | Your provider determines dosing. With or without DAC — ask your provider why they recommend their approach. |
For injection supplies and self-administration basics, see our Injectable Peptide Supplies Guide →
What Are the Side Effects and Risks?
- Injection site reactions.
- Water retention (usually mild and temporary).
- Blood sugar effects — GH compounds can affect glucose metabolism, monitor if pre-diabetic.
- Tingling or numbness in extremities.
- Headache.
- Potential interaction with diabetes medications.
Who Should NOT Use CJC-1295 / Ipamorelin?
If you have an active cancer or tumor history: GH and IGF-1 elevation are growth signals. While CJC-1295/Ipamorelin produces a more physiological GH pulse than synthetic HGH, the underlying concern is the same: stimulating growth pathways in someone with an active or recent malignancy is not a risk most oncologists would accept. This conversation belongs with your oncologist, not your peptide provider.
If you are diabetic or have blood sugar dysregulation: GH directly affects insulin sensitivity and glucose metabolism. If you are diabetic, pre-diabetic, or have a history of metabolic syndrome, CJC-1295/Ipamorelin can shift your glycemic control in ways that require active monitoring and possible medication adjustment. Your endocrinologist must be in the loop — not just informed after the fact.
If you are pregnant or breastfeeding: No safety data exists in pregnant or lactating populations. Absolute contraindication.
If you have an active pituitary disorder: These compounds work by stimulating your own pituitary to release GH. If your pituitary axis is already dysregulated — acromegaly, prolactinoma, hypopituitarism, or post-surgical pituitary changes — adding a secretagogue is not appropriate without endocrinology supervision.
If you are unwilling to get baseline labs: Baseline IGF-1 and fasting glucose are not optional with this protocol. They’re how you and your provider know whether the compound is doing what it’s supposed to and whether it’s causing harm you can’t feel. If a provider is willing to prescribe this without baseline labs, that is a red flag about the provider, not a feature.
What 'good' IGF-1 movement looks like depends on your goal. Worth understanding before reading any single follow-up.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include IGF-1, fasting glucose, fasting insulin, CBC, CMP, and a thyroid panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products.
- 1What are my baseline GH and IGF-1 levels?
- 2CJC-1295 with or without DAC — and why?
- 3What monitoring schedule do you recommend?
- 4How will we track whether this is working — labs, sleep data, body composition?
- 5Are there blood sugar concerns given my health history?
- 6How does this interact with any other medications or supplements I’m taking?
Is CJC-1295 / Ipamorelin Legal in 2026?
Both CJC-1295 and Ipamorelin are Category 2 and were referred to PCAC in September 2024. The committee reviewed Ipamorelin in October 2024 and CJC-1295 in December 2024 and voted against inclusion on the 503A bulks list in both cases. As of April 2026, there is no announced FDA pathway to revisit either compound — the PCAC rejection is the standing regulatory ruling.
This puts CJC-1295 / Ipamorelin in a different regulatory bucket than the peptides removed from Category 2 on April 22, 2026 (BPC-157, TB-500, KPV, MOTS-C, DSIP, Semax, Epitalon, GHK-Cu, Dihexa, LL-37, Melanotan II, PEG-MGF). Those compounds are in active FDA review with PCAC meetings scheduled. CJC-1295 / Ipamorelin already had their review and were rejected. Some providers continue to prescribe CJC / Ipa under narrow patient-specific 503A exceptions, but bulk compounded availability is not the regulatory state today.
How Do I Get CJC-1295 / Ipamorelin Through a Legitimate Provider?
These providers meet our evaluation criteria: verified medical license, labs required before prescribing, and medications sourced from licensed U.S. pharmacies.
Peter MD
Hormone optimization, peptides, and longevity. Labs required before prescribing.
Not available in ID, AL. Lab work not available in NY, NJ, RI.
Book a ConsultationWe continuously evaluate providers. New additions will appear here as they’re verified.
These are affiliate links. We may earn a commission if you book through them. This never influences our evidence ratings or recommendations.